Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/65786
Title: Cotrimoxazole prophylaxis decreases tuberculosis risk among Asian patients with HIV
Authors: Stephane Wen Wei Ku
Awachana Jiamsakul
Kedar Joshi
Mark Kristoffer Ungos Pasayan
Alvina Widhani
Romanee Chaiwarith
Sasisopin Kiertiburanakul
Anchalee Avihingsanon
Penh Sun Ly
Nagalingeswaran Kumarasamy
Cuong D. Do
Tuti P. Merati
Kinh Van Nguyen
Adeeba Kamarulzaman
Fujie Zhang
Man Po Lee
Jun Yong Choi
Junko Tanuma
Suwimon Khusuwan
Benedict Lim Heng Sim
Oon Tek Ng
Winai Ratanasuwan
Jeremy Ross
Wing Wai Wong
P. S. Ly
V. Khol
F. J. Zhang
H. X. Zhao
N. Han
M. P. Lee
P. C.K. Li
W. Lam
Y. T. Chan
N. Kumarasamy
S. Saghayam
C. Ezhilarasi
S. Pujari
K. Joshi
S. Gaikwad
A. Chitalikar
S. Sangle
V. Mave
I. Marbaniang
D. N. Wirawan
F. Yuliana
E. Yunihastuti
D. Imran
J. Tanuma
S. Oka
T. Nishijima
J. Y. Choi
S. Na
J. M. Kim
B. L.H. Sim
Y. M. Gani
N. B. Rudi
A. Kamarulzaman
S. F. Syed Omar
S. Ponnampalavanar
I. Azwa
R. Ditangco
M. L. Mationg
W. W. Wong
S. W.W. Ku
P. C. Wu
O. T. Ng
P. L. Lim
L. S. Lee
Z. Ferdous
A. vihingsanon
S. Gatechompol
P. Phanuphak
C. Phadungphon
S. Kiertiburanakul
A. Phuphuakrat
L. Chumla
N. Sanmeema
R. Chaiwarith
T. Sirisanthana
W. Kotarathititum
J. Praparattanapan
S. Khusuwan
P. Kantipong
P. Kambua
W. Ratanasuwan
R. Sriondee
K. V. Nguyen
H. V. Bui
D. T.H. Nguyen
D. T. Nguyen
C. D. Do
A. V. Ngo
L. T. Nguyen
A. H. Sohn
J. L. Ross
B. Petersen
D. A. Cooper
M. G. Law
Keywords: Medicine
Issue Date: 1-Mar-2019
Abstract: © 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society. Introduction: Cotrimoxazole (CTX) is recommended as prophylaxis against Pneumocystis jiroveci pneumonia, malaria and other serious bacterial infections in HIV-infected patients. Despite its in vitro activity against Mycobacterium tuberculosis, the effects of CTX preventive therapy on tuberculosis (TB) remain unclear. Methods: Adults living with HIV enrolled in a regional observational cohort in Asia who had initiated combination antiretroviral therapy (cART) were included in the analysis. Factors associated with new TB diagnoses after cohort entry and survival after cART initiation were analysed using Cox regression, stratified by site. Results: A total of 7355 patients from 12 countries enrolled into the cohort between 2003 and 2016 were included in the study. There were 368 reported cases of TB after cohort entry with an incidence rate of 0.99 per 100 person-years (/100 pys). Multivariate analyses adjusted for viral load (VL), CD4 count, body mass index (BMI) and cART duration showed that CTX reduced the hazard for new TB infection by 28% (HR 0.72, 95% CI l 0.56, 0.93). Mortality after cART initiation was 0.85/100 pys, with a median follow-up time of 4.63 years. Predictors of survival included age, female sex, hepatitis C co-infection, TB diagnosis, HIV VL, CD4 count and BMI. Conclusions: CTX was associated with a reduction in the hazard for new TB infection but did not impact survival in our Asian cohort. The potential preventive effect of CTX against TB during periods of severe immunosuppression should be further explored.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063688788&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/65786
ISSN: 17582652
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.